跳至主要内容
临床试验/NCT01099163
NCT01099163已完成不适用

Effect of Conjugated Linoleic Acid Alone and in Conjunction With Vitamin E on Insulin Sensitivity, Beta Cell Function, Markers of Inflammation, Body Fat Mass and Other Biochemical Indicators in Patients With Type 2 Diabetes Mellitus

Shahid Beheshti University of Medical Sciences2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2009年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
60
试验地点
2
主要终点
insulin sensitivity

研究概览

简要总结

Conjugated linoleic acids (CLAs) comprise a family of linoleic acid (18:2n-6; LA) isomers that are formed by biohydrogenation and oxidation processes in nature. The main form of CLA, cis-9, trans-11-18:2, can be produced directly by bacterial hydrogenation in the rumen or by delta-9 desaturation of the co-product vaccenic acid (trans-11-18:1) in most mammalian tissues including man. The second most abundant isomer of CLA is the trans-10, cis-12-18:2 form. Observations clearly emphasize that differences exist between mammalian species in their response to CLAs with mice being the most sensitive. The majority of studies on body compositional effects (i.e. fat loss, lean gain), on cancer and cardiovascular disease attenuation, on insulin sensitivity and diabetes and on immune function have been conducted with a variety of animal models. Recent studies indicate that some but not all of the effects observed in animals also pertain to human volunteers. Reports of detrimental effects of CLA intake appear to be largely in mice and due mainly to the trans-10, cis-12 isomer. Suggestions of possible deleterious effects in man due to an increase in oxidative lipid products (isoprostanes) with trans-10, cis-12 CLA ingestion require substantiation. Unresponsiveness to antioxidants of these non-enzymatic oxidation products casts some doubt on their physiological relevance. We hypothesized that supplementation with CLA + an antioxidant (vitamin E) in patients with diabetes mellitus may have beneficial effects on glycemic control and insulin sensitivity.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
30 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of type 2 diabetes mellitus > 5 years
  • HbA1c ≤ 9%
  • Overweight or obese (BMI ≥ 25 kg/m2 and ≤ 30 kg/m2)
  • Age ≥ 30 and ≤ 70 years (postmenopausal if female)
  • Stable medical therapy for past 3 months
  • Stable serum glucose for past 3 months (128-180 mg/Dl)
  • Age between 30 to 50
  • Use of metformin
  • TG < 240 mg/Dl
  • No alcohol, no insulin, no smoke
  • No pregnancy, no menopause

排除标准

  • Personal history of coronary heart disease
  • Cerebrovascular disease or vascular disease
  • Renal or hepatic disease
  • Inflammatory diseases and thyroid diseases within the last years
  • Use of drugs known to affect glycemic control, beta blockers, any change in daily activity profile, and diet

结局指标

主要结局

insulin sensitivity

beta cell function

glycosylated hemoglobin

次要结局

  • inflammatory mediators (TNF-alpha, Il-1beta, Il-6, CRP, adiponectin, leptin)
  • systolic and diastolic blood pressure
  • serum lipids (TG, LDL, HDL, LDL/HDL, ApoB100)
  • fibrinogen, PAI-1
  • body fat using bioimpedance
  • oxidative stress (MDA)

研究者

研究点 (2)

Loading locations...

相似试验